Wave Life Sciences (WVE) CFO awarded RSUs, options and sells shares for taxes

Rhea-AI Filing Summary

Wave Life Sciences’ Chief Financial Officer Kyle Moran reported routine equity compensation and a related tax sale. On February 5, 2026, he received 45,625 restricted share units that vest in four equal annual installments from February 8, 2027 through February 8, 2030, and a share option for 273,750 ordinary shares at an exercise price of $12.75 per share, vesting 25% on February 8, 2027 and 6.25% quarterly thereafter until February 8, 2030. Following these grants, he held 137,973 ordinary shares and 273,750 options directly. On February 9, 2026, he sold 3,588 ordinary shares at $13.45 per share to cover taxes triggered by RSU vesting under an automatic sale provision, leaving 134,385 ordinary shares owned directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moran Kyle

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/05/2026		A		45,625(1)	A	$0.00	137,973(2)	D
Ordinary Shares	02/09/2026		S(3)		3,588	D	$13.45	134,385	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$12.75	02/05/2026		A		273,750		(4)	02/05/2036	Ordinary Shares	273,750	$0.00	273,750	D

Explanation of Responses:

1. Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.

2. Includes 1,983 ordinary shares acquired on January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.

3. On February 9, 2026, the reporting person sold 3,588 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.

4. The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.

	/s/ Kyle Moran	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did WVE CFO Kyle Moran report on February 2026 Form 4?

Kyle Moran reported equity awards and a small tax-related sale. He received restricted share units, a large stock option grant, and sold 3,588 ordinary shares solely to cover tax withholding from RSU vesting under an automatic sale provision.

How many Wave Life Sciences (WVE) RSUs did the CFO receive and how do they vest?

He received 45,625 restricted share units. These RSUs vest in four equal annual installments of 25% each on February 8, 2027, 2028, 2029, and 2030, providing a long-term, time-based alignment with Wave Life Sciences’ future performance and employment continuity.

What stock options were granted to WVE CFO Kyle Moran in this Form 4 filing?

He was granted an option to buy 273,750 ordinary shares at an exercise price of $12.75. The option vests 25% on February 8, 2027, then 6.25% quarterly until February 8, 2030, incentivizing multi-year value creation at Wave Life Sciences.

Why did the WVE CFO sell 3,588 ordinary shares on February 9, 2026?

He sold 3,588 shares solely to cover taxes from RSU vesting. The sale was required automatically under his RSU agreement to satisfy tax withholding obligations associated with the February 8, 2026 restricted share unit vesting event.

How many Wave Life Sciences ordinary shares does the CFO own after these transactions?

After the reported February 2026 transactions, Kyle Moran directly owns 134,385 ordinary shares. This reflects his equity position after receiving RSUs, exercising no options, and selling 3,588 shares to satisfy tax withholding obligations tied to vested restricted share units.

Are the reported Wave Life Sciences insider transactions routine compensation-related events?

Yes, the filing describes standard equity compensation and related tax handling. It shows RSU and stock option grants with multi-year vesting schedules, plus an automatic share sale used solely to cover tax withholding from RSU vesting, typical for executive compensation.